Central Nervous System Findings on Functional Magnetic Resonance Imaging in Patients Before and After Treatment With Anticholinergic Medication

Michel A. Pontari, Feroze B. Mohamed, Steve Lebovitch, Shweta Moonat, Brett Lebed, Michael R. Ruggieri, Scott Faro

Research output: Contribution to journalArticle

Abstract

Purpose: Anticholinergic medications are commonly used to treat urinary urgency and frequency. Muscarinic receptors are located in areas beyond the detrusor muscle. In this study we measured changes in central nervous system activity in patients with lower urinary tract symptoms treated with tolterodine or a placebo. Materials and Methods: A total of 20 female patients with urinary frequency were randomized to 4 weeks of treatment with tolterodine or a placebo. Functional magnetic resonance imaging based on blood oxygenation level dependant imaging of the brain during bladder filling was performed before and after treatment. For each patient the bladder was filled by a urethral catheter and emptied 5 times. Results: Multiple brain areas showed significant activation with bladder filling compared to the empty state and many areas also showed deactivation. Overall brain activation with bladder filling was decreased after treatment in both groups. After treatment 2 areas of the parietal cortex (precuneus and postcentral gyrus) showed significantly greater activity in patients treated with tolterodine vs placebo. Two areas of the cerebellum (anterior lobe and culmen) showed significantly greater activity in the placebo group, and these were also areas of significant deactivation in the tolterodine group. Conclusions: Brain activity changes as well as the areas of activation after treatment of lower urinary tract symptoms in patients with an anticholinergic medication or placebo are different in the 2 groups. Whether this finding represents action at the central nervous system or the bladder level is not known.

Original languageEnglish (US)
Pages (from-to)1899-1905
Number of pages7
JournalJournal of Urology
Volume183
Issue number5
DOIs
StatePublished - May 1 2010
Externally publishedYes

Fingerprint

Cholinergic Antagonists
Urinary Bladder
Central Nervous System
Placebos
Magnetic Resonance Imaging
Lower Urinary Tract Symptoms
Parietal Lobe
Brain
Therapeutics
Urinary Catheters
Somatosensory Cortex
Muscarinic Receptors
Neuroimaging
Cerebellum
Muscles
Tolterodine Tartrate

Keywords

  • magnetic resonance imaging
  • overactive
  • urinary bladder
  • urination disorders

ASJC Scopus subject areas

  • Urology

Cite this

Central Nervous System Findings on Functional Magnetic Resonance Imaging in Patients Before and After Treatment With Anticholinergic Medication. / Pontari, Michel A.; Mohamed, Feroze B.; Lebovitch, Steve; Moonat, Shweta; Lebed, Brett; Ruggieri, Michael R.; Faro, Scott.

In: Journal of Urology, Vol. 183, No. 5, 01.05.2010, p. 1899-1905.

Research output: Contribution to journalArticle

Pontari, Michel A. ; Mohamed, Feroze B. ; Lebovitch, Steve ; Moonat, Shweta ; Lebed, Brett ; Ruggieri, Michael R. ; Faro, Scott. / Central Nervous System Findings on Functional Magnetic Resonance Imaging in Patients Before and After Treatment With Anticholinergic Medication. In: Journal of Urology. 2010 ; Vol. 183, No. 5. pp. 1899-1905.
@article{d670278631c5415480ea34e90ee966c0,
title = "Central Nervous System Findings on Functional Magnetic Resonance Imaging in Patients Before and After Treatment With Anticholinergic Medication",
abstract = "Purpose: Anticholinergic medications are commonly used to treat urinary urgency and frequency. Muscarinic receptors are located in areas beyond the detrusor muscle. In this study we measured changes in central nervous system activity in patients with lower urinary tract symptoms treated with tolterodine or a placebo. Materials and Methods: A total of 20 female patients with urinary frequency were randomized to 4 weeks of treatment with tolterodine or a placebo. Functional magnetic resonance imaging based on blood oxygenation level dependant imaging of the brain during bladder filling was performed before and after treatment. For each patient the bladder was filled by a urethral catheter and emptied 5 times. Results: Multiple brain areas showed significant activation with bladder filling compared to the empty state and many areas also showed deactivation. Overall brain activation with bladder filling was decreased after treatment in both groups. After treatment 2 areas of the parietal cortex (precuneus and postcentral gyrus) showed significantly greater activity in patients treated with tolterodine vs placebo. Two areas of the cerebellum (anterior lobe and culmen) showed significantly greater activity in the placebo group, and these were also areas of significant deactivation in the tolterodine group. Conclusions: Brain activity changes as well as the areas of activation after treatment of lower urinary tract symptoms in patients with an anticholinergic medication or placebo are different in the 2 groups. Whether this finding represents action at the central nervous system or the bladder level is not known.",
keywords = "magnetic resonance imaging, overactive, urinary bladder, urination disorders",
author = "Pontari, {Michel A.} and Mohamed, {Feroze B.} and Steve Lebovitch and Shweta Moonat and Brett Lebed and Ruggieri, {Michael R.} and Scott Faro",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.juro.2010.01.009",
language = "English (US)",
volume = "183",
pages = "1899--1905",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Central Nervous System Findings on Functional Magnetic Resonance Imaging in Patients Before and After Treatment With Anticholinergic Medication

AU - Pontari, Michel A.

AU - Mohamed, Feroze B.

AU - Lebovitch, Steve

AU - Moonat, Shweta

AU - Lebed, Brett

AU - Ruggieri, Michael R.

AU - Faro, Scott

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Purpose: Anticholinergic medications are commonly used to treat urinary urgency and frequency. Muscarinic receptors are located in areas beyond the detrusor muscle. In this study we measured changes in central nervous system activity in patients with lower urinary tract symptoms treated with tolterodine or a placebo. Materials and Methods: A total of 20 female patients with urinary frequency were randomized to 4 weeks of treatment with tolterodine or a placebo. Functional magnetic resonance imaging based on blood oxygenation level dependant imaging of the brain during bladder filling was performed before and after treatment. For each patient the bladder was filled by a urethral catheter and emptied 5 times. Results: Multiple brain areas showed significant activation with bladder filling compared to the empty state and many areas also showed deactivation. Overall brain activation with bladder filling was decreased after treatment in both groups. After treatment 2 areas of the parietal cortex (precuneus and postcentral gyrus) showed significantly greater activity in patients treated with tolterodine vs placebo. Two areas of the cerebellum (anterior lobe and culmen) showed significantly greater activity in the placebo group, and these were also areas of significant deactivation in the tolterodine group. Conclusions: Brain activity changes as well as the areas of activation after treatment of lower urinary tract symptoms in patients with an anticholinergic medication or placebo are different in the 2 groups. Whether this finding represents action at the central nervous system or the bladder level is not known.

AB - Purpose: Anticholinergic medications are commonly used to treat urinary urgency and frequency. Muscarinic receptors are located in areas beyond the detrusor muscle. In this study we measured changes in central nervous system activity in patients with lower urinary tract symptoms treated with tolterodine or a placebo. Materials and Methods: A total of 20 female patients with urinary frequency were randomized to 4 weeks of treatment with tolterodine or a placebo. Functional magnetic resonance imaging based on blood oxygenation level dependant imaging of the brain during bladder filling was performed before and after treatment. For each patient the bladder was filled by a urethral catheter and emptied 5 times. Results: Multiple brain areas showed significant activation with bladder filling compared to the empty state and many areas also showed deactivation. Overall brain activation with bladder filling was decreased after treatment in both groups. After treatment 2 areas of the parietal cortex (precuneus and postcentral gyrus) showed significantly greater activity in patients treated with tolterodine vs placebo. Two areas of the cerebellum (anterior lobe and culmen) showed significantly greater activity in the placebo group, and these were also areas of significant deactivation in the tolterodine group. Conclusions: Brain activity changes as well as the areas of activation after treatment of lower urinary tract symptoms in patients with an anticholinergic medication or placebo are different in the 2 groups. Whether this finding represents action at the central nervous system or the bladder level is not known.

KW - magnetic resonance imaging

KW - overactive

KW - urinary bladder

KW - urination disorders

UR - http://www.scopus.com/inward/record.url?scp=77950499853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950499853&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2010.01.009

DO - 10.1016/j.juro.2010.01.009

M3 - Article

VL - 183

SP - 1899

EP - 1905

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -